Cognivue, Inc.

Exercise Regularly (#tiptuesday)! Studies show that taking proactive steps may help reduce the risk of memory loss and other forms of cognitive decline[1]. Research supports a strong link between physical activity and brain health. It is recommended to get at least 150 minutes of moderate aerobic activity a week[2]. Any activity that gets the heart pumping counts as aerobic activity, such as walking, dancing, and biking. #modifiableriskfactor #prevention #healthandwellness #lifestyle #brainhealth #cognitivescreening #Cognivue References: 1. Dementia. (2022, September 20). Retrieved November 20, 2022, from https://bit.ly/3yQEfg8. 2. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition. Washington, DC: U.S. Department of Health and Human Services; 2018.

Cognivue, Inc. celebrates as even more progress is made in the fight against Alzheimer’s disease! Yesterday’s approval by the #FDA of #Kisunla was yet another important step forward in offering new treatment options for Alzheimer’s disease when diagnosed early. This approval continues to lay the groundwork for even more research and development in this area. This step forward ties so closely to Cognivue’s mission to provide cognitive assessment tools that assist healthcare providers with early-stage detection of cognitive changes. Early detection, using an assessment tool like Cognivue Clarity, helps identify individuals who may need a full work-up as part of the diagnostic process. Early diagnosis of Alzheimer’s disease allows for new treatment recommendations, like the newly FDA approved Kisunla, that have been shown to be effective in slowing down the progression of cognitive decline in persons who are amyloid positive and in earlier phases of the Alzheimer’s disease continuum—in either mild cognitive impairment (MCI) or mild dementia phases (and may no longer be options in later phases of the continuum). #kisunla #donanemab #alzheimers #alzheimersdisease #progress #FDA #earlydetection #cognitivehealth #makingadifference #brighterfuture https://bit.ly/3W7XzPj

Cognivue, Inc.'s FOCUS study, just published in June 2024 in The Journal of Alzheimer’s Disease, examined the use of Cognivue Clarity® as a valid measure of cognitive performance in a diverse population. Link: https://bit.ly/3RSGjLv Main Takeaways: 👍 Based on a diverse sample that reflects many of the demographic characteristics of the US population, study data suggest Cognivue Clarity offers a quick, valid, and reliable measure of cognitive functions with limited practice effects when compared to a gold standard neuropsychological testing instrument. 👍 Cognivue Clarity can be used to effectively evaluate cognitive performance and screen individuals for cognitive impairment over time and can improve detection of cognitive changes, including MCI, in community settings, which is important in early detection and screening for cognitive changes across diverse populations. #research #diversity #cognitivehealth #cognitivescreening #cognitivechanges #cognivue Reference: Galvin JE, Chang LC, Estes PW, et al. Cognitive Assessment with Cognivue Clarity®: Psychometric Properties and Normative Ranges in a Diverse Population. Journal of Alzheimer’s Disease. 2024 Jun 14. doi: 10.3233/JAD 240331. Online ahead of print.

Research has shown that early detection and people taking action when it matters most can prevent, delay, or slow the onset of cognitive decline [1]. The Lancet Commission reported that 40% of the risk factors for dementia can be modified with lifestyle changes [2]. And now we know that in cases of cognitive decline due to Alzheimer’s disease, the disease begins 20 years or more before memory loss and other symptoms develop [3]. There are lots of evidence-based recommendations out there to help individuals proactively manage lifestyle-related risk factors and medical conditions that may affect cognition (and conversely, cognition affects how risk factors and medical conditions are managed). As it's Alzheimer’s and Brain Awareness Month, we are reminded of how important it is for individuals to adopt a combination of key healthy lifestyle habits, develop good awareness of overall wellness, and optimize their cognition by taking early and proactive steps that may help reduce the risk of memory loss and other forms of cognitive decline [4]. Using cognitive assessment tools like Cognivue Clarity and Cognivue Thrive for early detection of cognitive changes allows individuals to address modifiable risk factors sooner, potentially changing the course of cognitive decline. #AlzheimersAndBrainAwarenessMonth #EndAlz #AlzheimersAwareness #GoPurple #earlydetectionmatters #cognitivescreening #brainhealth #modifiableriskfactors #cognivue References: [1] Reducing Risk of Alzheimer’s Disease. (2022, September 13). Centers for Disease Control and Prevention. https://bit.ly/4biZ1Ta [2] Livingston G et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 Aug 8;396(10248):413-44 [3] Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5) [4] Dementia. (2022, September 20). Retrieved November 20, 2022, from https://bit.ly/4bfwP3v

The FDA clearance of Leqembi and the recent endorsement of donanemab by an independent panel of advisors to the FDA point to the importance of early detection of cognitive changes as well as amyloid status. These new treatment options have been shown to be effective in slowing the progression of cognitive decline in persons who are amyloid positive and in earlier phases of the disease continuum—in either mild cognitive impairment (MCI) or mild dementia phases [1,2]. Mild Cognitive Impairment (MCI): - Amyloid-positive individuals who have mild yet subtle cognitive problems but without noticeable changes in their ability to perform their usual basic or instrumental activities of daily living. - Note: While every Alzheimer’s disease patient goes through this phase, not everyone with MCI progresses further [3]. Some either do not have further decline or show improvement in their cognition [4]. Dementia Due to AD - Mild: - Individuals who experiences cognitive problems that have become more noticeable over time and beginning to affect their ability to maintain their performance in day-to-day living (i.e. being able to manage their finances and medications on their own). They may begin to struggle and need help with certain daily living activities in order to maintain their usual level of functioning. Some cognitive changes are normal as we age, and all of us experience them, but not everyone has the more serious cognitive decline that come with Alzheimer’s disease or other dementias. Early detection of cognitive changes, using an assessment tool like Cognivue Clarity, helps identify individuals who may need a full work-up as part of the diagnostic process. Early diagnosis allows for treatment recommendations that could potentially change the course of cognitive decline—this may include one of the new drug(s) to slow the progression of early Alzheimer’s disease, and/or identification and reduction of risk factors. These same treatment recommendations may no longer be options in later phases of the Alzheimer’s disease continuum. With June being Alzheimer’s and Brain Awareness month, we want to raise awareness of the growing importance of early detection, especially as new drug(s) come to market requiring an early-stage diagnosis. #AlzheimersAndBrainAwarenessMonth #endalz #AlzheimersAwareness #thelongestday #mild #alzheimers #mildcognitiveimpairment #brainhealth #cognitivehealth #earlydetection #cognitivescreening Cognivue, Inc. Alzheimer's Association® Eisai U.S. Alzheimer’s Disease and Brain Health Eli Lilly and Company References: [1] https://bit.ly/4cpOKp7 [2] https://bit.ly/3zjRHt2 [3] Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5). [4] Canevelli M, et al. Spontaneous reversion of mild cognitive impairment to normal cognition...

Cognivue, Inc. is bringing awareness this June to Alzheimer’s and Brain Awareness Month. Given the increasing clinical research focus on preclinical Alzheimer’s disease to #endalz, the need to effectively screen/pre-screen for suitable study participants in Alzheimer’s disease trials is greater than ever. Data from a large sample of 1001 subjects from the Bio-Hermes study, funded by the Global Alzheimer's Platform Foundation, show that Cognivue Clarity is able to distinguish between cognitively normal, MCI and mild dementia diagnosis groups, as well as detect the presence of amyloid. Once screened using Cognivue Clarity, participants can be efficiently and effectively recruited for anti-amyloid trials. Our 10-minute self-administered digital cognitive assessment tool is based on an FDA-cleared technology, which serves to enrich recruitment and avoid potentially unnecessary screening assessments. Furthermore, their performance can be reliably tracked over time. Since inception, Cognivue has invested in developing its cognitive assessment platform to advance technologies used in screening for Alzheimer’s disease and other related dementias. Read the latest poster on Cognivue Clarity’s performance in the Bio-Hermes study: https://bit.ly/4eikdLF #AlzheimersAndBrainAwarenessMonth #ABAM #endalz #stopalz #AlzheimersAwareness #alzheimersdisease #alzheimers #mildcognitiveimpairement #brainhealth #earlydetection #cognitivescreening #DCA #biomarkers #GAP #biohermes

Here at Cognivue, Inc. we are raising awareness about Alzheimer’s disease and other dementias this June. As shared by Cognivue President, Paul W. Estes, “In honor of Alzheimer's and Brain Awareness Month, let's shine a light on the importance of brain health. For 15 years, my passion with Cognivue has been to empower healthcare professionals with innovative tools to assess cognitive function quickly and accurately. Together, we can take proactive steps towards better brain health and a brighter future.” Cognivue’s digital cognitive assessment tools are used for early detection of cognitive impairment. Let’s spread the word this June because early detection allows people to address cognitive issues sooner, potentially changing the course of cognitive decline and improving brain health. #AlzheimersAndBrainAwarenessMonth #EndAlz #AlzheimersAwareness #GoPurple #earlydetectionmatters #cognitivescreening #brainhealth #modifiableriskfactors #cognivue Alzheimer's Association®

Cognivue, Inc. was in attendance at the New Face of Aging 2024 Conference yesterday. Cognivue’s President, Paul W. Estes, was part of an important panel discussion at the conference titled, “Longevity; Enlightenment & Empowerment.” The panel also included Ed Begley, Jr., Rosie E. Curiel Cid, Psy.D., Narendra Kini, MD, arlener D. Turner, Ph.D., and was moderated by Joy Siegel, EdD, MBA. #allianceforaging #pathofaging #aging #community #advocacy #brainhealth #wellbeing #healthempowerment #technology #innovation #cognivue Alliance for Aging, Inc.

Looking forward to The New Face of Aging Annual Conference on May 30th, brought to you by the Alliance for Aging, Inc. Paul W. Estes, President of Cognivue, Inc., will be joining a group of expert panelists on the main stage in the afternoon. Speaker information: https://bit.ly/4amZGTg #allianceforaging #pathofaging #aging #community #advocacy #brainhealth #wellbeing #healthempowerment #technology #innovation #cognivue

Become a Certified Dementia Practitioner in just 1-day! Join the online certification program on June 6th that will be taught by Harvard Medical and M.I.T. Trained Neuroscientist Dr. Keith Darrow, PhD, CCC-A. Register at: https://bit.ly/44peCyI Cognivue, Inc. is proud to be a sponsor of this event which aligns closely with our mission to advance early detection of cognitive impairment in order to address modifiable risk factors sooner (Hearing Loss is the #1 modifiable risk factor for dementia). AuDExperts #audiology #dementia #prevention #modifiableriskfactors #earlydetection #qualityoflife #cognivue